Individualized risk assessment for use of hormone therapy in people with sickle cell disease

Maureen K Baldwin^{1

2}, Bethany Samuelson Bannow^{1

2}, Rachel P Rosovsky^{1

3}, Nancy Sokkary^{1

4}, Lakshmi V Srivaths^{1

5}

Affiliations

¹ Women and Girls with Blood Disorders Learning Action Network, Montclair, New Jersey, USA.
² Oregon Health & Science University, Portland, Oregon, USA.
³ Division of Hematology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
⁴ Department of Obstetrics and Gynecology, Children's Healthcare of Atlanta/Emory School of Medicine, Atlanta, Georgia, USA.
⁵ Department of Pediatrics, Gulf States Hemophilia and Thrombophilia Center, McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, USA.

Editorial

Maureen K Baldwin et al. Res Pract Thromb Haemost. 2023.

. 2023 Dec 15;8(1):102297.

doi: 10.1016/j.rpth.2023.102297. eCollection 2024 Jan.

Maureen K Baldwin^{1

2}, Bethany Samuelson Bannow^{1

2}, Rachel P Rosovsky^{1

3}, Nancy Sokkary^{1

4}, Lakshmi V Srivaths^{1

5}

¹ Women and Girls with Blood Disorders Learning Action Network, Montclair, New Jersey, USA.
² Oregon Health & Science University, Portland, Oregon, USA.
³ Division of Hematology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
⁴ Department of Obstetrics and Gynecology, Children's Healthcare of Atlanta/Emory School of Medicine, Atlanta, Georgia, USA.
⁵ Department of Pediatrics, Gulf States Hemophilia and Thrombophilia Center, McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, USA.

No abstract available

References

1. Pecker L.H., Burke A., Streiff M.B., Lanzkron S. Progestin-only contraception is first line for sickle cell disease: a comment on "Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias. Res Pract Thromb Haemost. 2023;7 - PMC - PubMed
1. Bala N., Stanek J., Rodriguez V., Villella A. Prevalence and risk factors for pulmonary embolism in pediatric sickle cell disease: a National Administrative Database Study. Pediatr Hematol Oncol. 2023;40:433–445. - PubMed
1. Ilerhunmwuwa N.P., Adeniran O., Inyang L., Wasifuddin M., Hakobyan N., Perry J.C., et al. Prevalence and outcomes of pulmonary embolism with sickle cell disease: analysis of the Nationwide Inpatient Sample, 2016-2020. Eur J Haematol. 2023;111:441–448. - PubMed